Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita

https://doi.org/10.20996/1819-6446-2016-12-1-101-105

Full Text:

Abstract

Currently there are no generally accepted guidelines for the use of rivaroxaban together with amiodarone, verapamil or diltiazem in patients with creatinine clearance (CrCl)<80 ml/min. Some researchers suggest that in renal failure amiodarone, verapamil and diltiazem contribute to a significant increase in plasma concentrations of rivaroxaban that is accompanied by increased risk of bleeding. According to preliminary calculations, it seems rational to reduce the dose of rivaroxaban when co-administered with these drugs: to 15 mg/day in patients with ClCr 50-79 ml/min and to 10 mg/day in patients with ClCr<50 ml/min.

About the Author

S. N. Bel'diev
Tver State Medical University. Sovetskaja ul. 4, Tver, 170100 Russia
Russian Federation


References

1. Sulimov V.A., Napalkov D.A., Sokolova A.A., et al. Anticoagulant therapy in everyday clinical practice: data of the retrospective cross-sectional study. Rational Pharmacother Cardiol 2015;11(2):116-23. In Russian (Сулимов В.А., Напалков Д.А., Соколова А.А. и др. Антикоагулянтная терапия в реальной клинической практике: данные ретроспективного одномоментного исследования. Рациональная фармакотерапия в кардиологии 2015;11(2):209-16).

2. Koroleva L.Y., Kolesnichenko I.V., Nosov V.P., et al. Prevention of thromboembolic complications in atrial fibrillation – rat poison or new oral anticoagulants: do we have a choice, and should we be afraid to make it? First clinical experience with rivaroxaban in Nizhny Novgorod. Rational Pharmacother Cardiol 2014;10(1):303-6. In Russian (Королева Л.Ю., Колесниченко И.В., Носов В.П. и др. Профилактика тромбоэмболических осложнений при фибрилляции предсердий – крысиный яд или новые пероральные антикоагулянты: есть ли у нас выбор, и стоит ли бояться его сделать? Первый клинический опыт применения ривароксабана в Нижнем Новгороде. Рациональная фармакотерапия в кардиологии 2014;10(1):303-6).

3. Mueck W., Stampfuss J., Kubitza D., Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014;53(1):1-16.

4. Food and Drug Administration. Draft guidance for industry. Drug interaction studies – study design, data analysis and implications for dosing and labeling. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf. Accessed by January 10, 2016.

5. Shulkin A.V., Yakusheva E.N., Popova N.M. The role of P-glycoprotein in rational pharmacotherapy in cardiology. Rational Pharmacother Cardiol 2013;9(6):701-7. In Russian (Щулькин А.В., Якушева Е.Н., Попова Н.М. Роль гликопротеина-Р в рациональной фармакотерапии в кардиологии. Рациональная Фармакотерапия в Кардиологии 2013;9(6):701-7).

6. The State Register of Medical Products. Xarelto (rivaroxaban) prescribing information. Available at: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=1310712&t=. Accessed by January 14, 2016. In Russian (Государственный реестр лекарственных средств. Инструкция по применению лекарственного препарата для медицинского применения Ксарелто (ривароксабан). Доступно на: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=1310712&t=. Дата доступа: 14.01.2016).

7. Rumyantsev A.A., Pokataev I.A., Kozlov T.V., Rumyantsev N.A. The problem of the use of new oral anticoagulants in cancer patients receiving chemotherapy. Rational Pharmacother Cardiol 2014;10(6):634-639. In Russian (Румянцев А.А., Покатаев И.А., Козлова Т.В., Румянцев Н.А. Проблема использования новых пероральных антикоагулянтов у онкологических пациентов, получающих химиотерапию. Рациональная фармакотерапия в кардиологии 2014;10(6):634-639).

8. National guidelines for the diagnosis and treatment of atrial fibrillation. Available at: http://www.scardio.ru/content/Guidelines/FP_rkj_13.pdf. Accessed by January 13, 2016. In Russian (Национальные рекомендации по диагностике и лечению фибрилляции предсердий. Доступно на: http://www.scardio.ru/content/Guidelines/FP_rkj_13.pdf. Дата доступа: 13.01.2016).

9. Diagnosis and treatment of atrial fibrillation. Russian recommendations. Rossiyskiy Kardiologicheskiy Zhurnal 2013;4(102):suppl 3:1-45. In Russian (Диагностика и лечение фибрилляций предсердий. Российские рекомендации. Российский Кардиологический Журнал 2013;4(102) приложение 3:1-45).

10. Heidbuchel H., Verhamme P., Alings M., et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15(5):625-51.

11. Javelov I.S. Practical features of rivaroxaban use for the prevention of cardioembolic complications in non-valvular atrial fibrillation. Trudnyj pacient 2014;12(10):16-22. In Russian (Явелов И.С. Практические особенности использования ривароксабана для профилактики кардиоэмболических осложнений при неклапанной фибрилляции предсердий. Трудный пациент 2014;12(10):16-22).

12. Shubik Ju.V. Antithrombotic therapy in atrial fibrillation. Vestnik aritmologii 2014;75:50-75. In Russian (Шубик Ю.В. Антитромботическая терапия при фибрилляции предсердий. Вестник аритмологии 2014;75:50-75).

13. European Medicines Agency. Xarelto: EPAR – Product Information. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Accessed by January 14, 2016.

14. Heidbuchel H., Verhamme P., Alings M., et al. Updated European Heart Rhythm As-sociation Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17(10):1467-507.

15. Webster's English dictionary, 2012: Meaning of MINOR in English. Available at: http://slovar-vocab. com/english/websters-vocab/minor-8348917.html. Accessed by January 18, 2016.

16. Steinberg B.A., Hellkamp A.S., Lokhnygina Y. et al. Use and outcomes of anti-arrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. Heart Rhythm 2014;11(6):925-32.

17. Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91.

18. Food and Drug Administration. Xarelto (rivaroxaban): full prescribing information. Issued: July 2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022406s000lbl.pdf. Accessed by January 06, 2016.

19. Food and Drug Administration. Xarelto (rivaroxaban): clinical pharmacology & biopharmaceutical review(s). December 30, 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022406Orig1s000ClinPharmR.pdf. Accessed by January 06, 2016.

20. Moore K.T., Vaidyanathan S., Natarajan J. et al. An open-label study to estimate the effect of steadystate erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function. J Clin Pharmacol 2014;54(12):1407-20.

21. Food and Drug Administration. Xarelto (rivaroxaban): full prescribing information. Revised: 9/2015. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202439s015lbl.pdf. Accessed by January 05, 2016.

22. Bel'diev S.N. Practical aspects of apixaban use in clinical practice: continuing the theme. Ration Pharmacother Cardiol 2015;11(5):543-47. In Russian (Бельдиев С.Н. Практические аспекты применения апиксабана в клинической практике: продолжение темы. Рациональная фармакотерапия в кардиологии. 2015;11(5):543-47).


For citation:


Bel'diev S.N. Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita. Rational Pharmacotherapy in Cardiology. 2016;12(1):101-105. (In Russ.) https://doi.org/10.20996/1819-6446-2016-12-1-101-105

Views: 5250


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)